Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

August 14, 2008

UK the model for US healthcare?

Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Donald Fleming, MD, Division Head of Hematology and OncologyDonald Fleming, MD
Division Head of Hematology and Oncology, Davis Health System, Inc.
Implications: In this election year some have encouraged adoption of socialized medical services UK healthcare is an example of what some in this country have said we need to model our future healthcare system The recent use of biologics such as the TKIs have resulted in options for thousands of advanced kidney cancer patients that would otherwise die of the illness UK says no to expensive tretments for advanced kidney cancer

Analysis:  This is yet another example of why jumping on the socialized medicine bandwagon can have dismal results. I can site several examples in my own practice where patients with metastaic renal cell cancer have had amazing responses to the recently made available TKIs. I agree they are expensive, but nothing in this world starts cheap. With time many drug prices moderate. Think wice before agreeing to have the Feds take over healthcare!

Other Analyses of the Same Source Article:
NICE States Novel Therapies for Renal Cell Cancer Too Costly
August 28, 2008, Author: Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Pharmaceutical Cost Transperancy
August 20, 2008, Author: GLG Expert Contributor
Improving the Quality of Life while living in our means
August 12, 2008, Author: GLG Expert Contributor
Fair or Unfair Decision: the cost of the drugs for kidney cancer is more than the economy can bear.
August 11, 2008, Author: GLG Expert Contributor
Medical treatment -- the unacknowledged Tragedy of the Commons
August 11, 2008, Author: GLG Expert Contributor
Federal Govt. Should be the cost
August 8, 2008, Author: GLG Expert Contributor

Report a Concern

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203